MINNEAPOLIS & SAN FRANCISCO--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today announced that patient enrollment in its CONNECTSM trial has concluded. The trial is assessing how the use of the Medtronic CareLink® Network to remotely monitor patients with the Concerto® cardiac resynchronization therapy-defibrillator (CRT-D) and Virtuoso® implantable cardioverter-defibrillator (ICD) effectively enables better patient care and reduces unnecessary healthcare costs. Principal investigator is George Crossley, M.D., chief of electrophysiology at Baptist Hospital and Mid-State Cardiology in Nashville, Tenn.
